Chief Regulatory and Development Officer · Aclaris Therapeutics, Inc. (ACRS)

Christopher Powala

FY2017 is the first fiscal year CompBrief holds for Christopher Powala as a named executive officer of Aclaris Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2017

$536,239

Salary $385,000Stock awards $0

2nd of 3 named executive officers at Aclaris Therapeutics by FY2017 total.

3 named officers on file for Aclaris Therapeutics, FY2017

Christopher Powala’s pay file — $29

  • 1 fiscal year of pay, line by line
  • ACRS’s disclosed peer group of 43 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aclaris Therapeutics’s whole pay program stands against its peers

  • Aclaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ACRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2018 (DEF 14A).

Free

Get Christopher Powala’s full pay file as a PDF — free

More than this page: up to 10 years of Christopher’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Christopher Powala compensation by year

Aclaris Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Aclaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017
Salary$385,000
Bonus$0
Stock awards$0
Option awards$0
Non-equity incentive$139,803
Pension and deferred compensation$0
All other$11,436
Total$536,239

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aclaris Therapeutics, Inc. DEF 14A filed April 26, 2018, accession 0001558370-18-003338, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aclaris Therapeutics, Inc. filed document, accession 0001558370-18-003338. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2018.

Equity holdings

unvested awards at FY2017 year-end
TypeUnvested unitsValue at year-endExercise price
RSU5,200$128,232—
RSU3,900$96,174—
RSU3,250$80,145—
Option46,800—$28.92
Option2,411—$0.72
Option9,819—$1.52
Option30,466—$10.66
Option29,258—$28.68

Per the Outstanding Equity Awards at Fiscal Year-End table in Aclaris Therapeutics, Inc.'s FY2017 proxy; value at the fiscal year-end close, as the company printed it.

Aclaris Therapeutics’s named executive officers, FY2017

as the company reported each
Named executive officerRoleFY2017 total
Neal WalkerPresident and Chief Executive Officer$809,586
Christopher Powala · this pageChief Regulatory and Development Officer$536,239
Stuart ShanlerChief Scientific Officer$534,078

The full Aclaris Therapeutics compensation record

free company brief

This page is one person within Aclaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Aclaris Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aclaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christopher Powala's compensation dossier · One-time report. No refunds.